This technology is the use of endoglin-specific antibodies to enhance the detection process of certain cancers, offering a more precise and reliable approach to identifying cancer-related variants of endoglin. Directed toward an antibody to a mutated endoglin protein, this antibody provides methods and compositions for detecting splice variants of the endoglin protein, enabling the accurate diagnosis of cancer.
Background: According to the American Cancer Society, as of 2025, pancreatic cancer accounts for about 3% of all cancers in the United States and about 7% of all cancer deaths. The need for a new pancreatic biomarker with increased efficiency is more necessary than ever as traditional methods fail to properly determine susceptibility and overall predictability. This innovation features two novel sequences of an endoglin protein for use as a new biomarker for pancreatic cancer determination.
Applications:
Advantages: